The effect of recombinant human growth hormone treatment on bone and mineral metabolism in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 13, Issue 6, 1998, Pages 1529-1534

  Gram, Jeppe ^a   Hansen, Tony Bill ^a   Jensen, Per Bruno ^a   Christensen, Jan Hardam ^b   Ladefoged, Søren ^c   Pedersen, Fritz Bangsgaard ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Fredericia Sygehus   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Alkaline phosphatase; Bone mineral density; Bone remodelling; C terminal type I collagen propeptide; Growth hormone treatment; Haemodialysis

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM ION; HUMAN GROWTH HORMONE; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; ALKALINE PHOSPHATASE; COLECALCIFEROL; MINERAL; PEPTIDE; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE I C TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMODIALYSIS; HUMAN; MALE; MALNUTRITION; MINERAL METABOLISM; NUTRITIONAL STATUS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; BIOCHEMICAL COMPOSITION; BONE DENSITOMETRY; BONE DISEASE; BONE TURNOVER; CHRONIC DISEASE; DRUG DOSE REDUCTION; DRUG EFFECT; FEMUR; HEMODIALYSIS PATIENT; MULTICENTER STUDY; PROTEIN BLOOD LEVEL; SOMATOMEDIN C BLOOD LEVEL; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; BONE AND BONES; BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MINERALS; NUTRITION DISORDERS; NUTRITIONAL STATUS; RENAL DIALYSIS;

EID: 0031749501     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.6.1529     Document Type: Article

References (22)

1. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803
2. Blake PG. Growth hormone and malnutrition in dialysis patients. Perit Dial Int 1995; 15: 210-216
3. Kopple JD. The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure. Miner Electrolyte Metab 1992; 18: 269-275
4. Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW. Effects of recombinant human growth hormone in adults receiving maintenance haemodialysis. J Am Soc Nephrol 1991; 2: 1130-1135
5. Ikizler TA, Wingard RL, Breyer JA et al. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 1994; 46: 1178-1183
6. Sinobe M, Sanaka T, Higuchi C, Hizuka N, Nihei H, Sugino N. The improvement of catabolic state in haemodialysis patients by recombinant human growth hormone (rhGH). J Am Soc Nephrol 1993; 4: 431
7. Kassem M, Blum W, Risteli J, Mosekilde L, Eriksen EF. Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif Tissue Int 1993; 52: 222-226
8. Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990; 5: 609-618
9. Hagiwara S, Aratani H, Miki T et al. Total body and regional bone mineral content in haemodialysis patients. Ann Nucl Med 1994; 8: 41-46
10. Binnerts A, Swart GR, Wilson JHP et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol 1992; 37: 79-87
11. Brixen K, Nielsen HK, Bouillon R, Flyvbjerg A, Mosekilde L. Effects of short term growth hormone treatment on PTH, calcitriol, thyroid hormones, insulin, and glucagon. Acta Endocrinol 1992; 127: 331-336
12. Caverzasio J, Montessuit C, Bonjour JP. Stimulatory effect of insulin-like growth factor-1 on renal Pi transport and plasma 1,25-dihydroxyvitamin D3. Endocrinology 1990; 127: 453-459
13. Hansen TB, Brixen K, Vahl N et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebocontrolled study. J Clin Endocrinol Metab 1996; 81: 3352-3359
14. Sharhon SA, Delmas PD, Malaval L et al. Serum bone glaprotein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 1986; 63: 892-897
15. Hamdy NAT, Risteli J, Risteli L et al. Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis? Nephrol Dial Transplant 1994; 9: 511-516
16. Mazzaferro S, Pasquali M, Ballanti P et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995; 10: 52-58
17. Jensen LT, Olesen HP, Risteli J, Lorenzen I. External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph. Lab Anim Sci 1990; 40: 620-624
18. Bollerslev J, Gram J, Nielsen HK et al. Effect of a short course of 1,25-dihydroxyvitamin D3 on biochemical markers of bone remodeling in adult male volunteers. Bone 1991; 12: 339-343
19. Rosen T, Johannsson G, Hallgren P, Caidahl K, Bosaeus I, Bengtsson BA, Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol Metab 1994; 1: 55-66
20. Abrahamsen B, Hansen TB, Høgsberg IM, Pedersen FB, Beck-Nielsen H. Impact of hemodialysis on dual X-ray absorptiometry, bioelectrical impedance measurements, and anthropometry. Am J Clin Nutr 1996; 63: 80-86
21. Thoren M, Soop M, Degerblad M, Saaf M. Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency. Acta Endocrinol 1993; 128 [Suppl 2]: 41-43
22. Degerblad M, Elgindy N, Hall K., Sjoberg HE, Thoren M. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol 1992; 126: 387-393